ADDED
The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2025, the last business day of the registrant s most recently completed second fiscal quarter, was $ 552.00 based upon the closing price reported for such date on The Nasdaq Capital Market.
On January 24, 2025, May 19, 2025, October 10, 2025 and March 26, 2026, the Registrant effected 1-for-100, 1-for-15, 1-for-8 and 1-for-25 reverse stock splits of its authorized shares of common stock, respectively.
Each reverse stock split was accompanied by a corresponding decrease in its issued and outstanding shares of common stock.
We may issue additional shares of common stock or preferred stock, including issuances upon exercise of outstanding pre-funded warrants, in connection with capital raising transactions and under an employee incentive plan, which issuances would significantly dilute the interest of our stockholders.
Business Overview CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., a Delaware corporation ( CDT , CDT Equity or the Company ), is a data-driven pharmaceutical development, focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.
The Company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments.
The Company s strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies with strong, supporting Phase I safety data.
Through advanced co-crystallization and solid-form technologies developed at our Cambridge facilities, the Company improves drug properties and extends patent life by up to 20 years.
In partnership with Sarborg Limited ( Sarborg ), the Company also applies AI-powered signature analysis to rapidly identify new therapeutic applications and combinations for existing compounds.
The Company s pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health.
REMOVED
The aggregate market value of the common stock held by non-affiliates of the registrant as of June 28, 2024, the last business day of the registrant s most recently completed second fiscal quarter, was $ 41,401,162 based upon the closing price reported for such date on The Nasdaq Global Market.
On January 25, 2025, the Registrant effected a 1-for-100 reverse stock split of its authorized shares of common stock, accompanied by a corresponding decrease in its issued and outstanding shares of common stock.
It is difficult to accurately predict the time and cost of development and of subsequently obtaining regulatory approval for AZD1656 as it employs newly developed technology.
We currently rely on agreements with a related party and third parties for the purpose of licensing our clinical assets.
In the near-term, we intend to rely on third parties for the licensing of clinical assets and those which may arise through future partnerships.
We may issue additional shares of common stock or preferred stock, including under an employee incentive plan, which would dilute the interest of our stockholders.
Business Overview On September 22, 2023, a merger transaction (the Business Combination ) between Conduit Pharmaceuticals Limited ( Old Conduit ), Murphy Canyon Acquisition Corp ( MURF ) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of MURF ( Merger Sub ), was completed pursuant to the Agreement and Plan of Merger, dated November 8, 2022, as amended, (the Merger Agreement ).
Pursuant to the terms of the Merger Agreement, at the closing, (i) Merger Sub merged with and into Old Conduit, with Old Conduit surviving the Business Combination as a wholly-owned subsidiary of MURF, and (ii) MURF changed its name from Murphy Canyon Acquisition Corp.
Conduit has developed a unique business model that allows it to act as a conduit to bring clinical assets from pharmaceutical companies and develop new treatments for patients.
Our novel approach addresses unmet medical needs and lengthens the intellectual property for our existing assets through cutting-edge solid-form technology and then commercializing these products with life science companies.